Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 13/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | GRM8 | O00222 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7649639 | 0.83 | BCHE (0.40) | TBXAS1EPHX2GRM8GRM4SMN1; SMN2 | |
| SCHEMBL8461160 | 0.76 | SMN1; SMN2 (0.47) | TBXAS1EPHX2SMN1; SMN2 | |
| SCHEMBL8581067 | 0.75 | FOLH1 (0.41) | — | |
| SCHEMBL7649464 | 0.75 | PTPRA (0.39) | SMN1; SMN2 | |
| SCHEMBL27965757 | 0.74 | TBXAS1 (0.60) | TBXAS1EPHX2GRM8GRM4SMN1; SMN2 | |
| SCHEMBL2638943 | 0.74 | TBXAS1 (0.60) | TBXAS1EPHX2GRM8GRM4SMN1; SMN2 | |
| SCHEMBL30082780 | 0.74 | TBXAS1 (0.60) | TBXAS1EPHX2GRM8GRM4SMN1; SMN2 | |
| SCHEMBL27965558 | 0.74 | TBXAS1 (0.60) | TBXAS1EPHX2GRM8GRM4SMN1; SMN2 | |
| SCHEMBL7650063 | 0.73 | LCK (0.34) | — | |
| SCHEMBL27497417 | 0.73 | TBXAS1 (0.58) | TBXAS1EPHX2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002515040-A | — | — | 2002-05-21 | — | — | JP | claimed |
| JP-2002514184-A | — | — | 2002-05-14 | — | — | JP | claimed |
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | claimed |
| EP-0954295-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |